secwatch.observer — SEC 8-K summary
======================================

Issuer:     NOVAVAX INC (NVAX)
CIK:        0001000694
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001628280-26-030924
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Novavax Q1 revenue $140M, net loss $9M; Pfizer Matrix-M deal adds $30M upfront
------------------------------------------------------------------------------

- Total revenue $140M, down 79% YoY; prior-year included $603M non-cash APA close-out.
- Net loss $9M vs net income $519M in Q1 2025; cash $795M, up from $751M.
- Pfizer non-exclusive Matrix-M license yielded $30M upfront, potential milestones up to $500M.
- Matrix-M partnering expanded: four top-10 pharma companies exploring over 30 fields; new MTAs signed.
- FY 2026 guidance reiterated: Non-GAAP combined R&D+SG&A $310-340M; cash position strengthened by $330M credit facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/0001628280-26-030924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1000694/000162828026030924/nvax-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-030924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer